Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer.

Argiris A, Karamouzis MV, Smith R, Kotsakis A, Gibson MK, Lai SY, Kim S, Branstetter BF, Shuai Y, Romkes M, Wang L, Grandis JR, Ferris RL, Johnson JT, Heron DE.

Ann Oncol. 2011 Nov;22(11):2482-8. doi: 10.1093/annonc/mdr002. Epub 2011 Mar 1.

2.

Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer.

Argiris A, Karamouzis MV, Gooding WE, Branstetter BF, Zhong S, Raez LE, Savvides P, Romkes M.

J Clin Oncol. 2011 Mar 20;29(9):1140-5. doi: 10.1200/JCO.2010.33.3591. Epub 2011 Feb 22.

3.

Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck.

Villaflor VM, Haraf D, Salama JK, Kocherginsky M, Langerman A, Gomez-Abuin G, Beniwal P, Blair EA, Stenson KM, Portugal L, Seiwert T, Williams RD, Dekker AJ, Witt ME, Vokes EE, Cohen EE.

Ann Oncol. 2011 Nov;22(11):2501-7. doi: 10.1093/annonc/mdq785. Epub 2011 Mar 8.

PMID:
21385883
4.

Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck.

Vermorken JB, Licitra L, Stöhlmacher-Williams J, Dietz A, Lopez-Picazo JM, Hamid O, Hossain AM, Chang SC, Gauler TC.

Eur J Cancer. 2013 Sep;49(13):2877-83. doi: 10.1016/j.ejca.2013.05.002. Epub 2013 May 30.

PMID:
23726971
5.

Phase I trial of dose-escalated cisplatin with concomitant cetuximab and hyperfractionated-accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck.

Kuhnt T, Sandner A, Wendt T, Engenhart-Cabillic R, Lammering G, Flentje M, Grabenbauer G, Schreiber A, Pirnasch A, Dunst J.

Ann Oncol. 2010 Nov;21(11):2284-9. doi: 10.1093/annonc/mdq216. Epub 2010 Apr 28.

PMID:
20427347
6.

Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial.

Kim ES, Neubauer M, Cohn A, Schwartzberg L, Garbo L, Caton J, Robert F, Reynolds C, Katz T, Chittoor S, Simms L, Saxman S.

Lancet Oncol. 2013 Dec;14(13):1326-36. doi: 10.1016/S1470-2045(13)70473-X. Epub 2013 Nov 12. Erratum in: Lancet Oncol. 2014 Jan;15(1):e4.

PMID:
24231627
7.

Pemetrexed plus cetuximab in patients with recurrent non-small cell lung cancer (NSCLC): a phase I/II study from the Hoosier Oncology Group.

Jalal S, Waterhouse D, Edelman MJ, Nattam S, Ansari R, Koneru K, Clark R, Richards A, Wu J, Yu M, Bottema B, White A, Hanna N.

J Thorac Oncol. 2009 Nov;4(11):1420-4. doi: 10.1097/JTO.0b013e3181b624ae.

8.

Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407.

Govindan R, Bogart J, Stinchcombe T, Wang X, Hodgson L, Kratzke R, Garst J, Brotherton T, Vokes EE.

J Clin Oncol. 2011 Aug 10;29(23):3120-5. doi: 10.1200/JCO.2010.33.4979. Epub 2011 Jul 11.

9.

Phase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III-IVB head and neck squamous cell carcinoma (HNSCC).

Fury MG, Sherman EJ, Rao SS, Wolden S, Smith-Marrone S, Mueller B, Ng KK, Dutta PR, Gelblum DY, Lee JL, Shen R, Kurz S, Katabi N, Haque S, Lee NY, Pfister DG.

Ann Oncol. 2014 Mar;25(3):689-94. doi: 10.1093/annonc/mdt579. Epub 2014 Feb 3.

10.

Phase I study of concurrent selective lymph node late course accelerated hyper-fractionated radiotherapy and pemetrexed, cisplatin for locally advanced esophageal squamous cell carcinoma.

Li BS, Gong HY, Huang W, Yi Y, Zhang ZC, Li HS, Wang ZT, Yu JM.

Dis Esophagus. 2011 May;24(4):251-7. doi: 10.1111/j.1442-2050.2010.01130.x. Epub 2010 Nov 12.

PMID:
21073623
11.

Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage III non-small cell lung cancer.

Gadgeel SM, Ruckdeschel JC, Patel BB, Wozniak A, Konski A, Valdivieso M, Hackstock D, Chen W, Belzer K, Burger AM, Marquette L, Turrisi A.

J Thorac Oncol. 2011 May;6(5):927-33. doi: 10.1097/JTO.0b013e3182156109.

12.

Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer.

Argiris A, Duffy AG, Kummar S, Simone NL, Arai Y, Kim SW, Rudy SF, Kannabiran VR, Yang X, Jang M, Chen Z, Suksta N, Cooley-Zgela T, Ramanand SG, Ahsan A, Nyati MK, Wright JJ, Van Waes C.

Clin Cancer Res. 2011 Sep 1;17(17):5755-64. doi: 10.1158/1078-0432.CCR-11-0861. Epub 2011 Jul 12.

13.

Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.

Smit EF, Burgers SA, Biesma B, Smit HJ, Eppinga P, Dingemans AM, Joerger M, Schellens JH, Vincent A, van Zandwijk N, Groen HJ.

J Clin Oncol. 2009 Apr 20;27(12):2038-45. doi: 10.1200/JCO.2008.19.1650. Epub 2009 Mar 23.

PMID:
19307503
14.

Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors.

Misset JL, Gamelin E, Campone M, Delaloge S, Latz JE, Bozec L, Fumoleau P.

Ann Oncol. 2004 Jul;15(7):1123-9.

PMID:
15205208
15.

Phase I trial of vinflunine and pemetrexed in refractory solid tumors.

Sanoff HK, Davies J, Walko C, Buie L, Chiu WK, Ivanova A, O'Neil B, Stinchcombe TE, Keller K, Dees EC.

Invest New Drugs. 2011 Feb;29(1):131-6. doi: 10.1007/s10637-009-9344-3. Epub 2009 Oct 15.

16.

Correlation between TS, MTHFR, and ERCC1 gene polymorphisms and the efficacy of platinum in combination with pemetrexed first-line chemotherapy in mesothelioma patients.

Powrózek T, Kowalski DM, Krawczyk P, Ramlau R, Kucharczyk T, Kalinka-Warzocha E, Knetki-Wróblewska M, Winiarczyk K, Dyszkiewicz W, Krzakowski M, Milanowski J.

Clin Lung Cancer. 2014 Nov;15(6):455-65. doi: 10.1016/j.cllc.2014.06.009. Epub 2014 Aug 15.

PMID:
25246386
17.

Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck.

Pivot X, Raymond E, Laguerre B, Degardin M, Cals L, Armand JP, Lefebvre JL, Gedouin D, Ripoche V, Kayitalire L, Niyikiza C, Johnson R, Latz J, Schneider M.

Br J Cancer. 2001 Sep 1;85(5):649-55.

18.

Phase II study of pemetrexed and cisplatin plus cetuximab followed by pemetrexed and cetuximab maintenance therapy in patients with advanced nonsquamous non-small cell lung cancer.

Schmid-Bindert G, Gebbia V, Mayer F, Arriola E, Márquez-Medina D, Syrigos K, Biesma B, Leschinger MI, Frimodt-Moller B, Ripoche V, Myrand SP, Nguyen TS, Hozak RR, Zimmermann A, Visseren-Grul C, Schuette W.

Lung Cancer. 2013 Sep;81(3):428-34. doi: 10.1016/j.lungcan.2013.05.010. Epub 2013 Jun 20.

PMID:
23790468
19.

A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.

Seiwert TY, Connell PP, Mauer AM, Hoffman PC, George CM, Szeto L, Salgia R, Posther KE, Nguyen B, Haraf DJ, Vokes EE.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):515-22.

20.

Phase I study of pemetrexed and cisplatin with concurrent high-dose thoracic radiation after induction chemotherapy in patients with unresectable locally advanced non-small cell lung cancer.

Mornex F, Peignaux K, Germain T, Wautot V, Chouaki N, Bourayou N, Tourani JM.

Lung Cancer. 2013 Apr;80(1):68-74. doi: 10.1016/j.lungcan.2012.12.007. Epub 2013 Jan 16.

PMID:
23332163

Supplemental Content

Support Center